Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01778530 · ClinicalTrials.gov registry record · Phase 2
TRC105 for Recurrent Glioblastoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01778530: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01778530 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01778530, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Background: \- Glioblastoma is an aggressive type of brain cancer that often resists treatment. TRC105 is an experimental drug that blocks the growth of new blood vessels. It is being studied for possible use in treating different kinds of cancer. Researchers want to see if TRC105 can be used to treat glioblastoma that has not responded to standard treatments. Objectives: \- To test the safety and effectiveness of TRC105 in adults who have glioblastoma that has not responded to standard treatments. Eligibility: \- Individuals at least 18 years of age who have glioblastoma that has not responded to standard treatments. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and other tests will be used to study the tumor before the start of treatment. * Participants will have 28-day (4-week) cycles of treatment. * Participants will have TRC105 intravenously once a week. The first infusion will take about 4 hours. The length of time needed for the infusion may be slowly reduced if it is well tolerated. * At the end of the first cycle (the first 4 weeks), the imaging studies will be repeated before continuing TRC105. * Participants will take TRC105 for as long as the tumor does not grow and the side effects are not too severe. They will have imaging studies at the end of every cycle to evaluate the tumor.
Interventions
- DRUG TRC105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01778530
The ClinicalTrials.gov registry entry for NCT01778530 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRC105 is the first listed.
NCT01778530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01778530 about?
NCT01778530 is a clinical study titled "TRC105 for Recurrent Glioblastoma". Background: \- Glioblastoma is an aggressive type of brain cancer that often resists treatment. TRC105 is an experimental drug that blocks the growth of new blood vessels. It is being studied for possible use in treating different kinds of cancer. Researchers want to see if TRC105 can be used to tr...
What is the current status of trial NCT01778530?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01778530?
The interventions under investigation include: TRC105 (DRUG).
Who is sponsoring clinical trial NCT01778530?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.